Entry Point Capital, LLC Pacira Bio Sciences, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 23,021 shares of PCRX stock, worth $608,675. This represents 0.2% of its overall portfolio holdings.
Number of Shares
23,021
Previous 15,959
44.25%
Holding current value
$608,675
Previous $240,000
80.42%
% of portfolio
0.2%
Previous 0.14%
Shares
4 transactions
Others Institutions Holding PCRX
# of Institutions
259Shares Held
49.7MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$212 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$139 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$86.3 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$59.7 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$52.7 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.21B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...